<DOC>
	<DOCNO>NCT00838617</DOCNO>
	<brief_summary>This study patient Amyotrophic Lateral Sclerosis ( ALS ) . We use muscle ultrasound tool try see change muscle size find fast ALS progressing . This might give u good way carry study new drug see might help slow progression ALS . Participants study muscle ultrasound perform muscle arm legs first visit , 3 month later , one last time 3 month . This take 10 minute , painless , involve scan muscle handheld device , gel apply skin . At visit , also questionnaire symptom strength testing .</brief_summary>
	<brief_title>Muscle Ultrasound : A New Tool Measuring Progression Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Protocol Study - Muscle Ultrasound : A New Tool Measuring Progression ALS A . Specific Aims The author propose study change muscle mass time patient ALS . Muscle atrophy common feature disease , clinical experience correlate progress weakness . As , qualitative marker disease progress , although lack quantitative marker . Muscle ultrasound safe , noninvasive , rapid method measure muscle volume thickness ( 1 ) . Recently Arts , et al publish assessment muscle ultrasound , specifically include reduce muscle depth increase ultrasound echogenicity ( 2 ) . We believe determine quantitatively rate progression muscle mass group patient ALS lead clinically useful tool serve marker disease progression , may useful clinical trial new therapy disease . B . Background Significance ALS quickly progressive disease result skeletal muscle weakness , include ventilatory weakness , ultimate cause death vast majority patient ALS . Median survival diagnosis le 3 year . There one drug approve treat ALS , riluzole , effect limit progression illness slight ( 6 ) . Current study design often use primary endpoint either death ALS initiation long-term mechanical ventilation ( LTMV ) . There tool assess progression , include questionnaire call ALS functional rating scale ( ALS-FRS ) , direct measurement strength , electromyography technique call motor unit number estimate ( MUNE ) . Each potential drawback , include potential lack objectivity questionnaire variable effort assess direct strength measurement . There also work correlate magnetic resonance spectroscopy finding progression ALS , positive result ( 3 ) . However , technology expensive , time consuming , widely available . Muscle ultrasound may sensitive enough quantitatively detect change muscle thickness ( 4 ) , may serve objective tool measure disease progression , purpose clinical trial . Muscle echointensity ( EI ) also abnormal ALS ( 2 , 4 ) , although assessment le reliable among different observer ultrasound setting , result less diagnostic precision . Normal value muscle thickness echointensity available , norm vary age weight ( 5 ) . Muscle ultrasound readily available , noninvasive , inexpensive , could use context clinical examination . Muscle ultrasound painless complete minute . C. Preliminary Studies/Progress Report As pilot study , preliminary data use muscle ultrasound longitudinally patient ALS . The study Arts et al use muscle ultrasound assist ALS diagnosis , knowledge , muscle ultrasound use detect longitudinal change illness . This study help development future study test pharmacologic agent ALS , provide muscle ultrasound validated endpoint progression ALS . D. Research Design Methods Ten patient recruited participate , serial muscle ultrasound examination every three month , regularly schedule clinic appointment Vanderbilt ALS clinic . Muscles examine include forearm flexor , biceps , tibialis anterior . The thickness muscle measure standard site muscle , addition echogenicity measure grayscale histogram representation . The rate loss ultrasound-measured muscle thickness assess time . Our hypothesis significant loss muscle thickness time , correlate disease severity . As different patient different rate deterioration , likely significant difference rate muscle volume loss patient patient . A secondary endpoint increase time muscle echogenicity . Patients complete ALS Functional Rating Scale ( ALSFRS-R ) , 12 item subjective scale assess several motor function , include function speech , swallow , respiration , activity daily live . Grip strength measure hand grip dynamometry , use best result 3 attempt limb . Secondary analysis also conduct correlate decrease ultrasound-measure muscle depth ALS Functional-Rating Scale , measure hand grip dynamometry . The study conduct period 8 month . All patient data keep password-secured online database call REDcap . Any adverse event report IRB , none expect safe diagnostic modality . E. Inclusion Criteria 1 . All patient must meet El Escorial criterion definite probable ALS . 2 . Patients force vital capacity ( FVC ) must exceed 50 % . F. Exclusion Criteria 1 . Patients primary lateral sclerosis ( PLS ) form motor neuron disorder participate . 2 . Patients severe weakness ALS require continuous mechanical ventilation , force vital capacity le 50 % , clinically measurable strength arm legs . 3 . Patients without cognitive capacity give inform consent . This clinical feature ALS , therefore patient would alternate diagnosis would prevent capacity . G. Privacy/Confidentiality This minimize use study number , label patient data study number identify information . The medical record number correspond study number store REDcap , secure , password-protected database . H. Human Subjects Research/Risks Careful consideration give protection subject research risk appropriate inclusion woman minority subject study . Research risk substantially limited noninvasive nature muscle ultrasound , absence pharmacologic intervention study . There theoretical risk breach confidentiality , minimize noted section . I . Reporting Adverse Events/Unanticipated Problems involve Risk Participants Others The PI report IRB event adverse event involve participant , study personnel , others , either procedure involve study , event breach participant confidentiality . These risk minimize note . J . Statistical Considerations As pilot study , power likely find statistically significant difference . Nonetheless , mixed effect model statistical evaluation change muscle ultrasound value carry analysis . K. Follow-up Record Retention At conclusion study , study data maintain electronically , secure , encrypt format PI REDcap 6 year . After time , data submit patient 's StarPanel electronic record destroyed .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>must meet El Escorial criterion definite probable ALS . force vital capacity ( FVC ) must exceed 50 % . Patients primary lateral sclerosis ( PLS ) form motor neuron disorder severe weakness ALS require continuous mechanical ventilation , force vital capacity le 50 % , clinically measurable strength arm leg . Patients without cognitive capacity give inform consent . ( This clinical feature ALS , therefore patient would alternate diagnosis would prevent capacity . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Ultrasonography</keyword>
	<keyword>Atrophy</keyword>
</DOC>